ArticleJournal of translational medicine2022
Autoimmunity is a hallmark of post-COVID syndrome.
Article in Journal of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 1 synthesis or guideline pooled it, 177 citations in OpenAlex.
- Anti-MDA5+ dermatomyositis following SARS-COV-2 infections: a systematic review.Frontiers in immunology · 2025Pooled it
- SARS-CoV-2-induced IgG repertoires shape T cell responses, microRNA regulation, and autoreactivity according to disease severity.Journal of translational autoimmunity · 2026Article
- Management of long COVID-19 in children and adolescents: from diagnosis to therapeutically approaches.Annals of medicine · 2026Review
- Emerging trends in post-COVID immune dysregulation: a narrative review.Annals of medicine and surgery (2012) · 2026Review
- Involvement of autoantibodies against G protein-coupled receptors in post-COVID condition and Chronic Fatigue Syndrome.Scientific reports · 2026Article
- Immune-metabolic trajectories delineate subgroups in paediatric long COVID.Nature communications · 2026Article
- Current status and future perspectives on the mechanistic and pathophysiological understanding of long COVID.Communications medicine · 2026Article
- Review
- NET Biomarkers in COVID-19 and Post-COVID Syndrome: a Comprehensive Analysis.Journal of clinical immunology · 2026Article
- A perfect storm: the immunological and pathophysiological landscape of pediatric post-COVID-19 condition.Frontiers in immunology · 2026Review
- Postural Orthostatic Tachycardia Syndrome, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID as Neuroimmune Disorders.ImmunoTargets and therapy · 2026Review
- Post-COVID fatigue disproportionately affects women: evidence from the DEFEAT Corona cohort.Frontiers in public health · 2026Article
- Lingering echoes of SARS-CoV-2: mechanistic insights and management of long COVID syndrome.Inflammopharmacology · 2026Review
- Autoantibodies in COVID-19 convalescent plasma donors.Vox sanguinis · 2026Article
- Demyelination and Cognitive Performance in Long COVID Patients with Insomnia and/or Depression.International journal of molecular sciences · 2025Article
- Article
- Post-steroid rebound in COVID-19 pneumonitis: a case series and review of the literature.BMC pulmonary medicine · 2025Review
- Distinct circulating autoantibodies are associated with COVID-19 hospitalization and SARS-CoV-2 neutralization activity.Npj viruses · 2025Article
- Brain-targeted autoimmunity is strongly associated with Long COVID and its chronic fatigue syndrome as well as its affective symptoms.Journal of advanced research · 2025Article
- Seasonal Coronavirus-Induced Immunological Imprinting and Previous Herpesvirus Infections in Patients With Long COVID.Journal of medical virology · 2025Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
- Comment on
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Autoimmunity has emerged as a characteristic of the post-COVID syndrome (PCS), which may be related to sex. In order to further investigate the relationship between SARS-CoV-2 and autoimmunity in PCS, a clinical and serological assessment on 100 patients was done. Serum antibody profiles against self-antigens and infectious agents were evaluated by an antigen array chip for 116 IgG and 104 IgM antibodies. Thirty pre-pandemic healthy individuals were included as a control group. The median age of patients was 49 years (IQR: 37.8 to 55.3). There were 47 males. The median post-COVID time was 219 (IQR: 143 to 258) days. Latent autoimmunity and polyautoimmunity were found in 83% and 62% of patients, respectively. Three patients developed an overt autoimmune disease. IgG antibodies against IL-2, CD8B, and thyroglobulin were found in more than 10% of the patients. Other IgG autoantibodies, such as anti-interferons, were positive in 5-10% of patients. Anti-SARS-CoV-2 IgG antibodies were found in > 85% of patients and were positively correlated with autoantibodies, age, and body mass index (BMI). Few autoantibodies were influenced by age and BMI. There was no effect of gender on the over- or under-expression of autoantibodies. IgG anti-IFN-λ antibodies were associated with the persistence of respiratory symptoms. In summary, autoimmunity is characteristic of PCS, and latent autoimmunity correlates with humoral response to SARS-CoV-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.